BMRN
BioMarin Pharmaceutical Inc.
Biotechnology · Healthcare · United States
68.53
close · 2026-08-13
value
91
cheaper than peers91
quality
64
stronger fundamentals64
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | 5.4% | 95 |
| cash flow yield, 2 years ago | 0.4% | 95 |
| earnings yield, 2 years ago | 1.3% | 95 |
| price to sales | 3.91× | 87 |
| earnings yield, 3 years ago | 1.1% | 86 |
| cash flow yield, 1 year ago | 3.6% | 86 |
| cash flow yield, 3 years ago | 0.3% | 86 |
| price to book | 2.10× | 83 |
| forward P/E | 10.34× | 82 |
| earnings yield, 1 year ago | 3.2% | 77 |
| earnings yield, latest year | 2.6% | 68 |
| EV to EBITDA | 24.30× | 47 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 21.2% | 84 |
| return on equity | 1.2% | 74 |
| revenue growth | 19.9% | 43 |
| debt to equity | 66.5% | 28 |
4 of 4 measures available
Facts
| market cap | $13B |
| free cash flow | $85.2M |
| employees | 3,221 |
| first trade | 1999-07-26 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.80 | 2.21 | 0.87 | 0.75 |
| free cash flow | $717.0M | $475.4M | $51.6M | $44.4M |
| net income | $348.9M | $426.9M | $167.6M | $141.6M |
| revenue | $3.22B | $2.85B | $2.42B | $2.10B |
| unusual items | $0 | $10.0M | $0 | $103.6M |